DD295850A5 - Verfahren zur herstellung neuer thienopyran-derivate - Google Patents
Verfahren zur herstellung neuer thienopyran-derivate Download PDFInfo
- Publication number
- DD295850A5 DD295850A5 DD90342098A DD34209890A DD295850A5 DD 295850 A5 DD295850 A5 DD 295850A5 DD 90342098 A DD90342098 A DD 90342098A DD 34209890 A DD34209890 A DD 34209890A DD 295850 A5 DD295850 A5 DD 295850A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- preparation
- general formula
- pyran
- filtered
- radical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- HJYUNRDQEQBDCG-UHFFFAOYSA-N 5H-thieno[3,2-b]pyran Chemical class C1=CCOC2=C1SC=C2 HJYUNRDQEQBDCG-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 230000004913 activation Effects 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- -1 2-oxo-1-pyrrolidinyl Chemical group 0.000 description 9
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- RUFPSEPHYSMUCR-UHFFFAOYSA-N 2h-pyran-2-carbonitrile Chemical compound N#CC1OC=CC=C1 RUFPSEPHYSMUCR-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DTCKWTYGYOJMAT-UHFFFAOYSA-N thieno[3,2-b]pyran-5-one Chemical compound O1C(=O)C=CC2=C1C=CS2 DTCKWTYGYOJMAT-UHFFFAOYSA-N 0.000 description 2
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 2
- 239000005052 trichlorosilane Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- JJSCUXAFAJEQGB-UHFFFAOYSA-N 1-isocyanatoethylbenzene Chemical compound O=C=NC(C)C1=CC=CC=C1 JJSCUXAFAJEQGB-UHFFFAOYSA-N 0.000 description 1
- PXZOREUXXJTZQP-UHFFFAOYSA-N 2H-pyran-6-ylcarbamic acid Chemical compound C1C=CC=C(O1)NC(=O)O PXZOREUXXJTZQP-UHFFFAOYSA-N 0.000 description 1
- MMTVHLPXGYWNOJ-UHFFFAOYSA-N 2h-pyran-2-carboxamide Chemical compound NC(=O)C1OC=CC=C1 MMTVHLPXGYWNOJ-UHFFFAOYSA-N 0.000 description 1
- GQBCZPRINVZQJQ-UHFFFAOYSA-N 3-hydroxythiophene-2-carbaldehyde Chemical compound OC=1C=CSC=1C=O GQBCZPRINVZQJQ-UHFFFAOYSA-N 0.000 description 1
- JIVGFTRLLYSYQT-UHFFFAOYSA-N 5,5-dimethylthieno[3,2-b]pyran Chemical compound C1=CC(C)(C)OC2=C1SC=C2 JIVGFTRLLYSYQT-UHFFFAOYSA-N 0.000 description 1
- FMTSVWMRLGLEPW-UHFFFAOYSA-N 5,5-dimethylthieno[3,2-b]pyran-2-carbaldehyde Chemical compound C1=CC(C)(C)OC2=C1SC(C=O)=C2 FMTSVWMRLGLEPW-UHFFFAOYSA-N 0.000 description 1
- ZZSLZQUPYGQPNA-UHFFFAOYSA-N 5,5-dimethylthieno[3,2-b]pyran-2-carbonitrile Chemical compound C1=CC(C)(C)OC2=C1SC(C#N)=C2 ZZSLZQUPYGQPNA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001562 benzopyrans Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HSNUIYJWTSJUMS-UHFFFAOYSA-N sodium;trimethyl(oxido)silane Chemical compound [Na+].C[Si](C)(C)[O-] HSNUIYJWTSJUMS-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT157389 | 1989-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD295850A5 true DD295850A5 (de) | 1991-11-14 |
Family
ID=3516340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90342098A DD295850A5 (de) | 1989-06-27 | 1990-06-26 | Verfahren zur herstellung neuer thienopyran-derivate |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5077307A (cs) |
| EP (1) | EP0405298B1 (cs) |
| KR (1) | KR910000743A (cs) |
| CN (1) | CN1025621C (cs) |
| AT (1) | ATE105559T1 (cs) |
| AU (1) | AU628995B2 (cs) |
| CA (1) | CA2019737A1 (cs) |
| CZ (1) | CZ280543B6 (cs) |
| DD (1) | DD295850A5 (cs) |
| DE (1) | DE59005666D1 (cs) |
| DK (1) | DK0405298T3 (cs) |
| ES (1) | ES2053015T3 (cs) |
| FI (1) | FI96312C (cs) |
| HR (1) | HRP940819A2 (cs) |
| HU (1) | HU204834B (cs) |
| IE (1) | IE63935B1 (cs) |
| IL (1) | IL94703A (cs) |
| LT (1) | LT3799B (cs) |
| LV (1) | LV10776A (cs) |
| MD (1) | MD121C2 (cs) |
| NO (1) | NO174423C (cs) |
| NZ (1) | NZ234084A (cs) |
| PT (1) | PT94487B (cs) |
| RU (1) | RU1833386C (cs) |
| SK (1) | SK317290A3 (cs) |
| UA (1) | UA15930A (cs) |
| YU (1) | YU124690A (cs) |
| ZA (1) | ZA904885B (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ230711A (en) * | 1988-09-23 | 1990-10-26 | Ortho Pharma Corp | Substituted thienopyrans as antihypertensive agents |
| DE3925719A1 (de) * | 1989-08-03 | 1991-02-07 | Bayer Ag | Substituierte thienopyranone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von parasiten |
| NZ240933A (en) * | 1990-12-21 | 1993-05-26 | Ortho Pharma Corp | Preparing enantiomerically pure thienopyran derivatives |
| GB9909792D0 (en) | 1998-12-04 | 1999-06-23 | Cambridge Bioclinical Limited | Potassium channel activators and their use |
| MD149Z5 (ro) * | 2009-09-17 | 2010-09-30 | Сергей Чербарь | Sigiliu cu fibre optice din polimer |
| MD4034C2 (ro) * | 2009-11-03 | 2010-11-30 | Сергей Чербарь | Sigiliu indicator pentru dispozitive metrologice |
| MD4230C1 (ro) * | 2012-11-29 | 2013-12-31 | Фёдор СЫРБУ | Sigiliu |
| MD861Z (ro) * | 2014-06-03 | 2015-07-31 | Александр КОРЕНКОВ | Sigiliu |
| MD4534C1 (ro) * | 2017-03-03 | 2018-06-30 | Сергей Чербарь | Sigiliu cu rotor blocabil pentru dispozitive metrologice |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0076075B1 (en) * | 1981-09-25 | 1986-11-20 | Beecham Group Plc | Pharmaceutically active benzopyran compounds |
| GB8308062D0 (en) * | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
| EP0205292B1 (en) * | 1985-06-08 | 1991-11-06 | Beecham Group Plc | Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
| GB8613786D0 (en) * | 1986-06-06 | 1986-07-09 | Beecham Group Plc | Active compounds |
| DE3881714D1 (de) * | 1987-02-04 | 1993-07-22 | Hoechst Ag | Alkylsubstituierte n-benzopyranyllactame, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen. |
| US4789525A (en) * | 1987-06-22 | 1988-12-06 | Eastman Kodak Company | Analytical method and multilayer element for total ionic iron determination |
| NZ230711A (en) * | 1988-09-23 | 1990-10-26 | Ortho Pharma Corp | Substituted thienopyrans as antihypertensive agents |
-
1990
- 1990-06-11 IE IE209790A patent/IE63935B1/en not_active IP Right Cessation
- 1990-06-12 IL IL9470390A patent/IL94703A/en not_active IP Right Cessation
- 1990-06-13 US US07/537,629 patent/US5077307A/en not_active Expired - Fee Related
- 1990-06-15 NZ NZ234084A patent/NZ234084A/en unknown
- 1990-06-19 AT AT9090111529T patent/ATE105559T1/de not_active IP Right Cessation
- 1990-06-19 ES ES90111529T patent/ES2053015T3/es not_active Expired - Lifetime
- 1990-06-19 DE DE59005666T patent/DE59005666D1/de not_active Expired - Fee Related
- 1990-06-19 DK DK90111529.5T patent/DK0405298T3/da not_active Application Discontinuation
- 1990-06-19 EP EP90111529A patent/EP0405298B1/de not_active Expired - Lifetime
- 1990-06-22 ZA ZA904885A patent/ZA904885B/xx unknown
- 1990-06-22 AU AU57787/90A patent/AU628995B2/en not_active Ceased
- 1990-06-23 KR KR1019900009322A patent/KR910000743A/ko not_active Ceased
- 1990-06-25 PT PT94487A patent/PT94487B/pt not_active IP Right Cessation
- 1990-06-25 FI FI903172A patent/FI96312C/fi not_active IP Right Cessation
- 1990-06-25 CA CA002019737A patent/CA2019737A1/en not_active Abandoned
- 1990-06-26 UA UA4830828A patent/UA15930A/uk unknown
- 1990-06-26 DD DD90342098A patent/DD295850A5/de not_active IP Right Cessation
- 1990-06-26 HU HU903998A patent/HU204834B/hu not_active IP Right Cessation
- 1990-06-26 NO NO902832A patent/NO174423C/no unknown
- 1990-06-26 RU SU904830828A patent/RU1833386C/ru active
- 1990-06-26 CZ CS903172A patent/CZ280543B6/cs unknown
- 1990-06-26 YU YU01246/90A patent/YU124690A/xx unknown
- 1990-06-26 SK SK3172-90A patent/SK317290A3/sk unknown
- 1990-06-27 CN CN90103312A patent/CN1025621C/zh not_active Expired - Fee Related
-
1993
- 1993-11-17 LV LV931243A patent/LV10776A/xx unknown
- 1993-12-14 LT LTIP1590A patent/LT3799B/lt not_active IP Right Cessation
-
1994
- 1994-05-24 MD MD94-0124A patent/MD121C2/ro not_active IP Right Cessation
- 1994-10-27 HR HRP-1246/90A patent/HRP940819A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0080602A1 (de) | Substituierte Benzimidazole, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende Arzneimittel | |
| EP0088274A1 (de) | Neue 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihrer Verwendung in Arzneimitteln | |
| DE2351412C2 (de) | 2,2-Disubstituierte 1-Oxo-5-indanyloxy-carbonsäuren, Verfahren zu deren Herstellung und Spaltung racemischer Gemische, sowie diese enthaltende Arzneimittel | |
| EP0088938B1 (de) | Verwendung von Pyridinverbindungen zur Herstellung von Arzneimitteln mit antihypoxischer und Ischämie-protektiver Wirkung | |
| EP0088940B1 (de) | Pyridincarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
| DD295850A5 (de) | Verfahren zur herstellung neuer thienopyran-derivate | |
| EP0052300A1 (de) | C-3 verknüpfte 1,4-Dihydropyridine, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung | |
| EP0003029A2 (de) | Neue 2-Oxo-1-pyrrolidinessigsäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Arzneimittel und deren Herstellung | |
| EP0019172B1 (de) | 6-Substituierte 11-Alkylen-morphantridine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
| DE3617976C2 (cs) | ||
| DE2726820A1 (de) | Imidazothiazine | |
| DE3721223C2 (cs) | ||
| CH630373A5 (de) | Verfahren zur herstellung neuer dihydro- und tetrahydro-iminothiazine. | |
| DE3038593A1 (de) | Neue entzuendungshemmende und immunregulatorische pyridine und pyrimidine | |
| EP0001108B1 (de) | Neue 1,4-Dihydropyridazine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| CH639067A5 (de) | Verfahren zur herstellung von zimtsaeureamiden. | |
| CH635342A5 (de) | Verfahren zur herstellung von neuen octahydro-indolo(2,3-a)-chinolizinen. | |
| EP0088323B1 (de) | Imidazothiadiazolalkencarbonsäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln | |
| CH639363A5 (de) | Bis/nitrosoureido/-polyol-derivate und verfahren zu ihrer herstellung. | |
| DE2609574C3 (de) | 1 -^-Fluor-S-trifluormethylthiophenyD-piperazin, dessen Salze, Verfahren zu dessen Herstellung und Arzneimittel | |
| EP0030343A1 (de) | Substituierte 2-Amino-3,4-dihydropyridinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| EP0110219B1 (de) | Heterocyclisch substituierte Nitrile, ihre Herstellung und Verwendung als Arzneimittel | |
| DE2711149C3 (de) | N-Substituierte[4-Chlor-6-(23-xylidino)-2· pyrimidinyl- thio] essigsäureamide sowie Verfahren zu deren Herstellung | |
| EP0313935A2 (de) | Enolether von 6-Chlor-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno(2,3-e)-1,2-thiazin-3-carbonsäureamid-1,1-dioxid, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
| DE1941933C3 (de) | Basisch substituierte 10,11- Dihydro-5,10-endoxa-SH-dibenzo- [a,d] -cycloheptene und deren pharmakologisch verträgliche Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PV | Patent disclaimer (addendum to changes before extension act) |